Pangaea Oncology SA

As of December 31, 2025, Pangaea Oncology SA carries a market capitalization of 62.13M, placing it among publicly traded companies globally. Its enterprise value stands at 65.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pangaea Oncology SA's next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2025, Pangaea Oncology SA has 35.91M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Pangaea Oncology SA maintains a current ratio of 1.78, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Pangaea Oncology SA's stock has declined approximately 15.88% over the past 52 weeks. The 50-day moving average sits at 1.48, while the 200-day moving average is 1.58.

As of December 31, 2025, Pangaea Oncology SA holds 3.07M in cash and equivalents against 5.82M in total debt, resulting in a net debt position of 3.81M. Total book value stands at 21.30M, with working capital of 5.62M providing operational flexibility.

Pangaea Oncology SA's most recent stock split took place on June 7, 2022 with a 883:896 split ratio.